Correlation between genetic alteration and long‐term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p

Abstract

BACKGROUND In oligodendroglial tumors, allelic losses on chromosome arms 1p and 19q are not only diagnostic molecular markers but also statistically significant predictors of both chemosensitivity and longer recurrence‐free survival. In the current study, the authors attempted to analyze 21 patients genetically and clinically, with special emphasis on the correlation between genetic alterations and long‐term therapeutic results. METHODS The authors reviewed the clinical cases of 21 patients who had undergone surgery for oligodendroglial tumors (13 oligodendrogliomas, World Health Organization [WHO] Grade II; 3 anaplastic oligodendrogliomas, WHO Grade III; 3 oligoastrocytomas, WHO Grade II; and 2 anaplastic oligoastrocytomas, WHO Grade III). Genetic testing for 1p deletions was performed using fluorescence in situ hybridization, and testing for 1p, 17p, and 19q deletions was carried out by microsatellite analysis. Survival was analyzed with univariate and multivariate Cox regression models. In addition, a high‐resolution deletion map of 1p, which led to the discovery of a new deleted region on 1p, was obtained. RESULTS Statistical analysis revealed that both loss of 1p and loss of 19q independently and significantly predicted overall survival. A high‐resolution deletion map, which displayed unusually narrow deletions, revealed a new region of deletion between D1S513 and D1S458 (1p34.3–36.11). CONCLUSIONS One of the putative tumor suppressor loci exists more proximally than ever reported. Based on the observation that 1p and 19q deletions predicted survival, the authors suggest further use of diagnostic and prognostic genetic testing in the clinical setting. Cancer 2003;97:2254–61. © 2003 American Cancer Society. DOI 10.1002/cncr.11322

Cutis tricolor parvimaculata: A Distinct Neurocutaneous Syndrome?

“…In this malignant brain tumor, loss of genetic material frequently involves chromosomes 1p and 19q, as likewise documented in the present case [11, 12]. Remarkably, in the family described by Westerhof et al [10], some patients showed mental deficiency or pyramidal tract disease.…”

Molecular Diagnostics in Central Nervous System Tumors

“…Mapping of occasional tumors with partial LOH have yielded ''regions of minimal deletion'' on 1p36 and 19q13.3, though many of the deletion-defining tumors were not oligodendrogliomas. 54,96,105,106 In line with that hypothesis is the general observation that in contrast to those with whole arm losses, tumors harboring small interstitial deletions tend to have an astrocytic morphology 107 and are often biologically aggressive (unpublished data). Thus, it is unclear that these regions truly harbor oligodendroglioma-specific genes.…”

Cerebrospinal Fluid (Vascular Endothelial Growth Factor) and Serologic (Recoverin) Tumor Markers for Malignant Glioma

“…3,4 However, despite high specificity, this test has limited sensitivity and is intensive and costly. 5 Furthermore, it requires actual tumor tissue sample from a craniotomy or brain biopsy, making its usefulness in patient surveillance both cumbersome and difficult. A tumor marker from serum or cerebrospinal fluid (CSF) would be easier to collect, quantify, and reproduce and also more practical in clinical practice.…”